Navigation Links
PathSensors Demonstrates Breakthrough Mail Security Screening Solution at National Postal Forum 2017
Date:4/26/2017

Baltimore bio tech firm, PathSensors, Inc., announced today it will be demonstrating its new Bioflash MailGuardtm mail security screening solution at the National Postal Forum 2017 in Baltimore, Maryland, May 21st through May 24th. The Bioflash MailGuard system provides a fast, highly accurate, easy to use and low cost threat detection solution for government and commercial mail room operations that need to screen mail and packages for potential threats such as anthrax. The system is now in use at major commercial mail room screening facilities.

“Government agencies, document management companies, outsourced mail room screening operators and commercial mail room managers need a turn key bio threat detection solution that has no false alarms; is fast to detect threats and is able to handle high volumes of mail and packages; is easy to use, and, above all, has a much lower cost of ownership than alternative approaches,” commented Ted Olsen, CEO, PathSensors, Inc. “The Bioflash MailGuard meets these requirements and the results – as demonstrated by a successful field launch earlier this year with a major commercial mail room operation – show that the Bioflash MailGuard is a true breakthrough technology. We are excited to be able to demonstrate the MailGuard with our partner, DualDraw, at the National Postal Forum.”

The BioFlashTM MailGuard System consists of an integrated biological testing unit, down flow booth, mail jogger, and compact medical refrigerator and requires standard 110v power to operate. The biological testing unit has the ability to connect to the Internet via an optional tethered laptop computer, which permits remote system diagnostics and secondary testing confirmation as needed. It can detect over 25 biological threats in concentrations as low as 100 CFU in less than five minutes.    The Bioflash MailGuard uses PathSensor’s CANARY technology, which is currently deployed by Defense and Homeland Security customers, and which can be Integrated with x-ray, chemical and other threat detection technologies. PathSensors will be exhibiting at Booth # 1024, at the National Postal Forum (http://www.npf.org) in Baltimore, May 21st to May 24th.

About PathSensors, Inc.
PathSensors is a leading biotechnology solutions and environmental testing company. PathSensors provides high speed, highly sensitive pathogen and threat detection solutions for the defense, homeland security, public health, medical countermeasures, mail room screening, first responder, food processing and agricultural sectors. PathSensors’ innovative BioFlash and Zephyr detection systems use CANARY® technology licensed from the MIT-Lincoln Laboratory and are deployed by government and commercial agencies due to their speed, accuracy and ease-of-use. For more information, visit http://www.pathsensors.com.

Read the full story at http://www.prweb.com/releases/2017/04/prweb14273297.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. PathSensors Launches Low Cost, High Speed Anthrax and Bio Threat Detection Solution for Mail Security Screening
2. PathSensors to Develop and Commercialize Bio Sensor Technology to Combat Citrus Greening Disease (HLB)
3. Dr. Greg Lamka joins PathSensors Scientific Advisory Board
4. PathSensors Moves to the Columbus Center in Baltimores Inner Harbor
5. BESI Full Scale Advanced Gasification Research Facility in University Park, Il Demonstrates Clean Waste Conversion for US Military
6. Kineta RLR Agonist Demonstrates Tumor Regression and an Adaptive Immune Response in Colon Carcinoma Model
7. Celltex autologous stem cell case study published in Stem Cells and Development demonstrates favorable response in pediatric patients
8. ProMetics PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis ("IPF") Phase 2 Clinical Trial
9. New Clinical Study Demonstrates Feasibility of Performing Multiplex ANA Testing on Whole Blood via Finger-Stick in Physician Office Near-Patient Setting
10. Bird Rock Bios Gerilimzumab, an Anti-IL-6 Antibody, Demonstrates Potential for Affordable Global Access to a Novel Biologic to Treat Rheumatoid Arthritis
11. Preliminary Results from Phase I/II Study of Epacadostat in Combination with Pembrolizumab presented at SITC 2015 Demonstrates 53% ORR across a Number of Cancer Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2020)... ... August 13, 2020 , ... Inc. magazine today ... most prestigious ranking of the nation’s fastest-growing private companies. The list represents a ... segment—its independent small businesses. Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many other ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a highly regarded ... on the purchase of greenfield for a new, expanded manufacturing facility. The site ... acres in the initial acquisition, with an option to purchase an additional 21 ...
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON Manufacturing, the leader in ... “BUILDING FOR LIFE.” The adoption of this taglines comes at a time of ... capacity to provide patients with urgently needed vaccines and other lifesaving pharmaceutical treatments. ...
(Date:7/31/2020)... ... 2020 , ... eSource has long been touted as the solution to high ... eSource, the reasons it did not take off as quickly as people initially expected, ... is moving towards capturing data electronically for clinical trials and then repurposing it for ...
Breaking Biology Technology:
(Date:8/26/2020)... ... August 25, 2020 , ... ... in partnership with Essex Bio-Technology, a bio-pharmaceutical company specializing in Ophthalmology and ... study of SkQ1 ophthalmic solution in patients with moderate to severe Dry ...
(Date:8/21/2020)... ... August 18, 2020 , ... ... therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved ... asset, SBI-101, for the treatment of severe COVID-19. Approval of this IND allows ...
(Date:8/12/2020)... ... 2020 , ... Both Roche, based in Basel, Switzerland, and ... with Housey Pharma’s HMI subsidiary to gain access to its core-enabling technology for ... Development spending in excess of US $10 billion. , Scientists at Housey Pharma ...
Breaking Biology News(10 mins):